25 XP   0   0   10

Actinogen Medical Ltd
Buy, Hold or Sell?

Let's analyse Actinogen together

PenkeI guess you are interested in Actinogen Medical Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Actinogen Medical Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Actinogen Medical Ltd

I send you an email if I find something interesting about Actinogen Medical Ltd.

Quick analysis of Actinogen (30 sec.)










What can you expect buying and holding a share of Actinogen? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
40.0%

What is your share worth?

Current worth
A$0.01
Expected worth in 1 year
A$-0.01
How sure are you?
60.0%

+ What do you gain per year?

Total Gains per Share
A$-0.01
Return On Investment
-41.2%

For what price can you sell your share?

Current Price per Share
A$0.03
Expected price per share
A$0.025 - A$0.0375
How sure are you?
50%

1. Valuation of Actinogen (5 min.)




Live pricePrice per Share (EOD)

A$0.03

Intrinsic Value Per Share

A$-0.05 - A$-0.02

Total Value Per Share

A$-0.04 - A$-0.02

2. Growth of Actinogen (5 min.)




Is Actinogen growing?

Current yearPrevious yearGrowGrow %
How rich?$8.8m$14.3m-$5.5m-62.2%

How much money is Actinogen making?

Current yearPrevious yearGrowGrow %
Making money-$7.1m-$6.2m-$830.4k-11.7%
Net Profit Margin-220.0%-260.9%--

How much money comes from the company's main activities?

3. Financial Health of Actinogen (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#668 / 992

Most Revenue
#387 / 992

Most Profit
#510 / 992

Most Efficient
#566 / 992

What can you expect buying and holding a share of Actinogen? (5 min.)

Welcome investor! Actinogen's management wants to use your money to grow the business. In return you get a share of Actinogen.

What can you expect buying and holding a share of Actinogen?

First you should know what it really means to hold a share of Actinogen. And how you can make/lose money.

Speculation

The Price per Share of Actinogen is A$0.032. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Actinogen.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Actinogen, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.01. Based on the TTM, the Book Value Change Per Share is A$0.00 per quarter. Based on the YOY, the Book Value Change Per Share is A$0.00 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Actinogen.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps0.00-8.8%0.00-8.8%0.00-7.8%0.00-6.4%0.00-4.8%
Usd Book Value Change Per Share0.00-6.8%0.00-6.8%0.003.5%0.00-0.6%0.001.1%
Usd Dividend Per Share0.000.0%0.000.0%0.009.5%0.003.6%0.001.8%
Usd Total Gains Per Share0.00-6.8%0.00-6.8%0.0013.0%0.003.0%0.002.9%
Usd Price Per Share0.03-0.03-0.03-0.03-0.03-
Price to Earnings Ratio-9.54--9.54--13.49--24.25--33.90-
Price-to-Total Gains Ratio-12.32--12.32-8.07-7.64--1.90-
Price to Book Ratio7.65-7.65-5.89-7.89-11.38-
Price-to-Total Gains Ratio-12.32--12.32-8.07-7.64--1.90-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.0211776
Number of shares47219
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share0.000.00
Usd Total Gains Per Share0.000.00
Gains per Quarter (47219 shares)-102.9645.26
Gains per Year (47219 shares)-411.86181.05
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-412-422219-38171
21-824-834438-76352
31-1237-1246657-114533
41-1649-1658877-152714
52-2061-20701096-190895
62-2473-24821315-2291076
72-2885-28941534-2671257
83-3298-33061753-3051438
93-3710-37181972-3431619
103-4122-41302191-3811800

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.016.02.00.0%
Book Value Change Per Share0.01.00.00.0%2.01.00.066.7%2.03.00.040.0%5.05.00.050.0%8.010.00.044.4%
Dividend per Share1.00.00.0100.0%3.00.00.0100.0%4.00.01.080.0%4.00.06.040.0%4.00.014.022.2%
Total Gains per Share0.01.00.00.0%2.01.00.066.7%3.02.00.060.0%6.04.00.060.0%9.09.00.050.0%

Fundamentals of Actinogen

About Actinogen Medical Ltd

Actinogen Medical Limited, a biotechnology company, develops therapies for neurological and neuropsychiatric diseases associated with dysregulated brain cortisol in Australia. It is developing Xanamem, an inhibitor of the 11ß-HSD1 enzyme, which is in Phase 2 clinical trials that achieves target engagement in the central nervous system, depression with cognitive impairment, Alzheimer's disease, and anxiety, sleep, and behavioral problems in fragile X syndrome. The company was formerly known as Actinogen Limited and changed its name to Actinogen Medical Limited in November 2015. Actinogen Medical Limited was incorporated in 1999 and is based in Sydney, Australia.

Fundamental data was last updated by Penke on 2024-06-04 06:46:02.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is overpriced.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Actinogen Medical Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Actinogen earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare¬†Actinogen to the¬†Biotechnology industry mean.
  • A Net Profit Margin of -220.0%¬†means that¬†$-2.20 for each $1¬†in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Actinogen Medical Ltd:

  • The MRQ is -220.0%. The company is making a huge loss. -2
  • The TTM is -220.0%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-220.0%TTM-220.0%0.0%
TTM-220.0%YOY-260.9%+40.9%
TTM-220.0%5Y-206.6%-13.3%
5Y-206.6%10Y-532.2%+325.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-220.0%-178.5%-41.5%
TTM-220.0%-223.7%+3.7%
YOY-260.9%-245.1%-15.8%
5Y-206.6%-390.8%+184.2%
10Y-532.2%-503.2%-29.0%
1.1.2. Return on Assets

Shows how efficient Actinogen is using its assets to generate profit.

  • Above 5% is considered healthy¬†but always compare¬†Actinogen to the¬†Biotechnology industry mean.
  • -70.7% Return on Assets means that¬†Actinogen generated¬†$-0.71 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Actinogen Medical Ltd:

  • The MRQ is -70.7%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -70.7%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-70.7%TTM-70.7%0.0%
TTM-70.7%YOY-40.8%-29.9%
TTM-70.7%5Y-47.7%-23.0%
5Y-47.7%10Y-40.2%-7.5%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-70.7%-11.6%-59.1%
TTM-70.7%-11.6%-59.1%
YOY-40.8%-10.9%-29.9%
5Y-47.7%-12.9%-34.8%
10Y-40.2%-14.1%-26.1%
1.1.3. Return on Equity

Shows how efficient Actinogen is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare¬†Actinogen to the¬†Biotechnology industry mean.
  • -80.2% Return on Equity means Actinogen generated $-0.80¬†for each¬†$1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Actinogen Medical Ltd:

  • The MRQ is -80.2%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -80.2%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-80.2%TTM-80.2%0.0%
TTM-80.2%YOY-43.7%-36.5%
TTM-80.2%5Y-51.7%-28.5%
5Y-51.7%10Y-43.0%-8.7%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-80.2%-13.9%-66.3%
TTM-80.2%-14.9%-65.3%
YOY-43.7%-13.5%-30.2%
5Y-51.7%-18.2%-33.5%
10Y-43.0%-19.0%-24.0%

1.2. Operating Efficiency of Actinogen Medical Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Actinogen is operating .

  • Measures how much profit Actinogen makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare¬†Actinogen to the¬†Biotechnology industry mean.
  • An Operating Margin of -324.7%¬†means the company generated $-3.25 ¬†for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Actinogen Medical Ltd:

  • The MRQ is -324.7%. The company is operating very inefficient. -2
  • The TTM is -324.7%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-324.7%TTM-324.7%0.0%
TTM-324.7%YOY-361.9%+37.2%
TTM-324.7%5Y-287.0%-37.7%
5Y-287.0%10Y-615.2%+328.2%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-324.7%-344.0%+19.3%
TTM-324.7%-235.7%-89.0%
YOY-361.9%-262.3%-99.6%
5Y-287.0%-383.7%+96.7%
10Y-615.2%-485.1%-130.1%
1.2.2. Operating Ratio

Measures how efficient Actinogen is keeping operating costs low.

  • Below 1 is considered healthy (always compare to¬†Biotechnology industry mean).
  • An Operation Ratio of 3.25 means that the operating costs are $3.25 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Actinogen Medical Ltd:

  • The MRQ is 3.247. The company is inefficient in keeping operating costs low. -1
  • The TTM is 3.247. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ3.247TTM3.2470.000
TTM3.247YOY3.619-0.372
TTM3.2475Y3.105+0.143
5Y3.10510Y6.338-3.233
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ3.2473.092+0.155
TTM3.2473.353-0.106
YOY3.6193.564+0.055
5Y3.1054.836-1.731
10Y6.3386.187+0.151

1.3. Liquidity of Actinogen Medical Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Actinogen is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to¬†Biotechnology industry mean).
  • A Current Ratio of 7.04¬†means the company has $7.04 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Actinogen Medical Ltd:

  • The MRQ is 7.043. The company is very able to pay all its short-term debts. +2
  • The TTM is 7.043. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ7.043TTM7.0430.000
TTM7.043YOY13.799-6.757
TTM7.0435Y14.847-7.804
5Y14.84710Y17.558-2.711
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ7.0433.776+3.267
TTM7.0434.034+3.009
YOY13.7994.978+8.821
5Y14.8475.984+8.863
10Y17.5586.360+11.198
1.3.2. Quick Ratio

Measures if Actinogen is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but¬†always compare¬†Actinogen to the¬†Biotechnology industry mean.
  • A Quick Ratio of 6.98¬†means the company can pay off $6.98 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Actinogen Medical Ltd:

  • The MRQ is 6.985. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 6.985. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ6.985TTM6.9850.000
TTM6.985YOY13.729-6.744
TTM6.9855Y14.570-7.585
5Y14.57010Y17.978-3.408
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ6.9853.198+3.787
TTM6.9853.631+3.354
YOY13.7294.843+8.886
5Y14.5705.825+8.745
10Y17.9786.378+11.600

1.4. Solvency of Actinogen Medical Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Actinogen assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare¬†Actinogen to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.12¬†means that Actinogen assets are¬†financed with 11.8% credit (debt) and the remaining percentage (100% - 11.8%)¬†is financed by its owners/shareholders.¬†

Let's take a look of the Debt to Asset Ratio trends of Actinogen Medical Ltd:

  • The MRQ is 0.118. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.118. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.118TTM0.1180.000
TTM0.118YOY0.067+0.051
TTM0.1185Y0.072+0.047
5Y0.07210Y0.060+0.012
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1180.336-0.218
TTM0.1180.346-0.228
YOY0.0670.284-0.217
5Y0.0720.367-0.295
10Y0.0600.376-0.316
1.4.2. Debt to Equity Ratio

Measures if Actinogen is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but¬†always compare¬†Actinogen to the¬†Biotechnology industry mean.
  • A Debt to Equity ratio of 13.4% means that company has $0.13 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Actinogen Medical Ltd:

  • The MRQ is 0.134. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.134. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.134TTM0.1340.000
TTM0.134YOY0.072+0.062
TTM0.1345Y0.078+0.056
5Y0.07810Y0.065+0.013
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1340.382-0.248
TTM0.1340.421-0.287
YOY0.0720.371-0.299
5Y0.0780.447-0.369
10Y0.0650.476-0.411

2. Market Valuation of Actinogen Medical Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Actinogen generates.

  • Above 15 is considered overpriced but¬†always compare¬†Actinogen to the¬†Biotechnology industry mean.
  • A PE ratio of -9.54 means the investor is paying $-9.54¬†for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Actinogen Medical Ltd:

  • The EOD is -7.520. Based on the earnings, the company is expensive. -2
  • The MRQ is -9.542. Based on the earnings, the company is expensive. -2
  • The TTM is -9.542. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-7.520MRQ-9.542+2.021
MRQ-9.542TTM-9.5420.000
TTM-9.542YOY-13.490+3.948
TTM-9.5425Y-24.250+14.709
5Y-24.25010Y-33.897+9.647
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-7.520-2.473-5.047
MRQ-9.542-2.865-6.677
TTM-9.542-2.837-6.705
YOY-13.490-3.461-10.029
5Y-24.250-6.135-18.115
10Y-33.897-6.468-27.429
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Actinogen Medical Ltd:

  • The EOD is -9.257. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -11.745. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -11.745. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.257MRQ-11.745+2.488
MRQ-11.745TTM-11.7450.000
TTM-11.745YOY-13.457+1.712
TTM-11.7455Y-47.943+36.198
5Y-47.94310Y-54.593+6.650
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.257-3.046-6.211
MRQ-11.745-3.513-8.232
TTM-11.745-3.609-8.136
YOY-13.457-4.805-8.652
5Y-47.943-7.882-40.061
10Y-54.593-8.502-46.091
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Actinogen is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy¬†(always compare to Biotechnology industry mean).
  • A PB ratio of 7.65 means the investor is paying $7.65¬†for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Actinogen Medical Ltd:

  • The EOD is 6.031. Based on the equity, the company is overpriced. -1
  • The MRQ is 7.652. Based on the equity, the company is overpriced. -1
  • The TTM is 7.652. Based on the equity, the company is overpriced. -1
Trends
Current periodCompared to+/- 
EOD6.031MRQ7.652-1.621
MRQ7.652TTM7.6520.000
TTM7.652YOY5.893+1.759
TTM7.6525Y7.885-0.233
5Y7.88510Y11.381-3.496
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD6.0312.012+4.019
MRQ7.6522.185+5.467
TTM7.6522.227+5.425
YOY5.8932.447+3.446
5Y7.8853.726+4.159
10Y11.3814.199+7.182
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Actinogen Medical Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Actinogen Medical Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.003-0.0030%0.002-295%0.000-91%0.001-731%
Book Value Per Share--0.0050.0050%0.009-38%0.006-15%0.0050%
Current Ratio--7.0437.0430%13.799-49%14.847-53%17.558-60%
Debt To Asset Ratio--0.1180.1180%0.067+76%0.072+65%0.060+97%
Debt To Equity Ratio--0.1340.1340%0.072+86%0.078+72%0.065+107%
Dividend Per Share--0.0000.0000%0.005-100%0.002-100%0.001-100%
Eps---0.004-0.0040%-0.004-12%-0.003-27%-0.002-46%
Free Cash Flow Per Share---0.003-0.0030%-0.004+9%-0.003-24%-0.002-41%
Free Cash Flow To Equity Per Share---0.003-0.0030%0.001-373%0.000-96%0.000-1028%
Gross Profit Margin--1.4441.4440%1.337+8%1.339+8%1.275+13%
Intrinsic Value_10Y_max---0.020--------
Intrinsic Value_10Y_min---0.048--------
Intrinsic Value_1Y_max---0.002--------
Intrinsic Value_1Y_min---0.003--------
Intrinsic Value_3Y_max---0.006--------
Intrinsic Value_3Y_min---0.011--------
Intrinsic Value_5Y_max---0.010--------
Intrinsic Value_5Y_min---0.021--------
Market Cap80861437.952-27%102592949.402102592949.4020%128114840.755-20%129125608.730-21%132208451.052-22%
Net Profit Margin---2.200-2.2000%-2.609+19%-2.066-6%-5.322+142%
Operating Margin---3.247-3.2470%-3.619+11%-2.870-12%-6.152+89%
Operating Ratio--3.2473.2470%3.619-10%3.105+5%6.338-49%
Pb Ratio6.031-27%7.6527.6520%5.893+30%7.885-3%11.381-33%
Pe Ratio-7.520+21%-9.542-9.5420%-13.490+41%-24.250+154%-33.897+255%
Price Per Share0.032-27%0.0410.0410%0.051-20%0.051-21%0.052-22%
Price To Free Cash Flow Ratio-9.257+21%-11.745-11.7450%-13.457+15%-47.943+308%-54.593+365%
Price To Total Gains Ratio-9.712+21%-12.322-12.3220%8.072-253%7.639-261%-1.903-85%
Quick Ratio--6.9856.9850%13.729-49%14.570-52%17.978-61%
Return On Assets---0.707-0.7070%-0.408-42%-0.477-33%-0.402-43%
Return On Equity---0.802-0.8020%-0.437-46%-0.517-36%-0.430-46%
Total Gains Per Share---0.003-0.0030%0.006-152%0.001-327%0.001-335%
Usd Book Value--8872894.8878872894.8870%14387450.599-38%10477382.529-15%8899599.9070%
Usd Book Value Change Per Share---0.002-0.0020%0.001-295%0.000-91%0.000-731%
Usd Book Value Per Share--0.0040.0040%0.006-38%0.004-15%0.0040%
Usd Dividend Per Share--0.0000.0000%0.003-100%0.001-100%0.001-100%
Usd Eps---0.003-0.0030%-0.002-12%-0.002-27%-0.002-46%
Usd Free Cash Flow---5780717.112-5780717.1120%-6300381.664+9%-4415750.641-24%-3415208.907-41%
Usd Free Cash Flow Per Share---0.002-0.0020%-0.002+9%-0.002-24%-0.001-41%
Usd Free Cash Flow To Equity Per Share---0.002-0.0020%0.001-373%0.000-96%0.000-1028%
Usd Market Cap53514099.637-27%67896013.91467896013.9140%84786401.612-20%85455327.857-21%87495552.906-22%
Usd Price Per Share0.021-27%0.0270.0270%0.034-20%0.034-21%0.035-22%
Usd Profit---7115852.286-7115852.2860%-6285359.466-12%-5212723.026-27%-3858879.958-46%
Usd Revenue--3234835.3833234835.3830%2409006.268+34%2500444.659+29%1846093.615+75%
Usd Total Gains Per Share---0.002-0.0020%0.004-152%0.001-327%0.001-335%
 EOD+3 -5MRQTTM+0 -0YOY+9 -275Y+4 -3210Y+7 -29

4.2. Fundamental Score

Let's check the fundamental score of Actinogen Medical Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-7.520
Price to Book Ratio (EOD)Between0-16.031
Net Profit Margin (MRQ)Greater than0-2.200
Operating Margin (MRQ)Greater than0-3.247
Quick Ratio (MRQ)Greater than16.985
Current Ratio (MRQ)Greater than17.043
Debt to Asset Ratio (MRQ)Less than10.118
Debt to Equity Ratio (MRQ)Less than10.134
Return on Equity (MRQ)Greater than0.15-0.802
Return on Assets (MRQ)Greater than0.05-0.707
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Actinogen Medical Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
RsiGreater than5055.881
Ma 20Greater thanMa 500.029
Ma 50Greater thanMa 1000.030
Ma 100Greater thanMa 2000.031
OpenGreater thanClose0.032
Total2/5 (40.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets15,209
Total Liabilities1,802
Total Stockholder Equity13,407
 As reported
Total Liabilities 1,802
Total Stockholder Equity+ 13,407
Total Assets = 15,209

Assets

Total Assets15,209
Total Current Assets12,688
Long-term Assets2,520
Total Current Assets
Cash And Cash Equivalents 8,460
Net Receivables 4,124
Inventory 0
Other Current Assets 105
Total Current Assets  (as reported)12,688
Total Current Assets  (calculated)12,688
+/-0
Long-term Assets
Property Plant Equipment 113
Intangible Assets 2,408
Other Assets 0
Long-term Assets  (as reported)2,520
Long-term Assets  (calculated)2,520
+/- 0

Liabilities & Shareholders' Equity

Total Current Liabilities1,802
Long-term Liabilities87
Total Stockholder Equity13,407
Total Current Liabilities
Short-term Debt 87
Accounts payable 1,101
Other Current Liabilities 613
Total Current Liabilities  (as reported)1,802
Total Current Liabilities  (calculated)1,802
+/-0
Long-term Liabilities
Capital Lease Obligations 87
Long-term Liabilities  (as reported)87
Long-term Liabilities  (calculated)87
+/-0
Total Stockholder Equity
Common Stock78,712
Retained Earnings -68,692
Accumulated Other Comprehensive Income 10,585
Other Stockholders Equity -7,198
Total Stockholder Equity (as reported)13,407
Total Stockholder Equity (calculated)13,407
+/-0
Other
Capital Stock78,712
Cash And Equivalents7,180
Cash and Short Term Investments 8,460
Common Stock Shares Outstanding 1,875,607
Current Deferred Revenue-87
Liabilities and Stockholders Equity 15,209
Net Debt -8,373
Net Invested Capital 13,407
Net Tangible Assets 11,000
Net Working Capital 10,887
Property Plant and Equipment Gross 144
Short Long Term Debt Total 87



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-30
> Total Assets 
53
268
2,942
2,008
1,342
1,141
466
276
1,262
15,579
12,950
10,210
18,026
16,222
11,936
18,378
23,306
15,209
15,20923,30618,37811,93616,22218,02610,21012,95015,5791,2622764661,1411,3422,0082,94226853
   > Total Current Assets 
0
0
2,598
1,861
1,119
907
286
138
1,154
10,021
7,744
5,364
13,429
12,527
8,164
15,056
20,417
12,688
12,68820,41715,0568,16412,52713,4295,3647,74410,0211,1541382869071,1191,8612,59800
       Cash And Cash Equivalents 
44
48
2,541
1,850
1,085
861
204
113
1,128
9,806
752
1,895
9,897
7,637
5,040
13,422
16,370
8,460
8,46016,37013,4225,0407,6379,8971,8957529,8061,1281132048611,0851,8502,5414844
       Short-term Investments 
0
0
0
0
0
0
0
0
0
0
4,026
2,095
0
0
0
0
0
0
0000002,0954,0260000000000
       Net Receivables 
2
50
57
11
33
30
23
4
0
182
2,605
1,215
3,158
4,603
2,662
1,544
3,942
4,124
4,1243,9421,5442,6624,6033,1581,2152,605182042330331157502
       Other Current Assets 
0
164
3
1
2
15
59
21
26
215
361
160
374
287
461
90
105
105
10510590461287374160361215262159152131640
   > Long-term Assets 
0
0
343
147
223
234
180
138
108
5,558
5,205
4,846
4,490
3,660
3,772
3,322
2,889
2,520
2,5202,8893,3223,7723,6604,4904,8465,2055,55810813818023422314734300
       Property Plant Equipment 
7
6
13
106
148
144
137
120
107
7
8
2
0
391
391
254
169
113
11316925439139102871071201371441481061367
       Long Term Investments 
0
0
0
0
0
0
0
0
2
0
0
0
0
0
0
0
0
0
000000000200000000
       Intangible Assets 
0
0
0
16
16
16
16
16
0
5,551
5,197
4,843
4,490
3,660
3,346
3,033
2,720
2,408
2,4082,7203,0333,3463,6604,4904,8435,1975,55101616161616000
       Other Assets 
0
0
0
0
0
0
0
0
0
0
0
0
107
35
35
35
0
0
00353535107000000000000
> Total Liabilities 
29
60
82
105
174
95
119
81
50
223
824
844
768
557
1,048
920
1,566
1,802
1,8021,5669201,048557768844824223508111995174105826029
   > Total Current Liabilities 
29
60
82
105
174
95
119
81
50
223
824
844
768
557
744
755
1,480
1,802
1,8021,480755744557768844824223508111995174105826029
       Short-term Debt 
0
0
0
0
0
0
0
0
0
0
4,026
2,095
0
86
86
71
78
87
877871868602,0954,0260000000000
       Accounts payable 
0
0
79
103
170
29
9
10
9
192
690
649
507
283
47
392
899
1,101
1,101899392472835076496901929109291701037900
       Other Current Liabilities 
29
39
4
3
4
66
110
71
41
30
134
195
261
275
611
292
502
613
613502292611275261195134304171110664343929
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
0
0
0
304
304
165
87
87
87871653043040000000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
304
165
87
0
08716530400000000000000
> Total Stockholder Equity
24
208
2,859
1,902
1,168
1,046
347
194
1,212
15,357
12,125
9,366
17,258
15,665
10,889
17,458
21,740
13,407
13,40721,74017,45810,88915,66517,2589,36612,12515,3571,2121943471,0461,1681,9022,85920824
   Retained Earnings -68,692-57,939-48,442-44,527-39,196-29,309-23,078-19,888-16,254-10,823-10,383-10,218-8,689-7,947-7,209-6,28200
   Accumulated Other Comprehensive Income 
0
0
4,819
4,789
4,792
4,815
4,789
4,789
4,789
5,356
5,705
5,865
7,168
7,296
7,491
7,780
9,068
10,585
10,5859,0687,7807,4917,2967,1685,8655,7055,3564,7894,7894,7894,8154,7924,7894,81900
   Capital Surplus 000000000000000000
   Treasury Stock000000000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.




Cash Flow

Currency in AUD. All numbers in thousands.




Income Statement

Currency in AUD. All numbers in thousands.